Medicus Pharma Seeks FDA Compassionate‑Use OK for Skinject in Gorlin Syndrome Patients

Medicus Pharma (NASDAQ: MDCX) is moving ahead with a plan to secure compassionate‑use approval from the Food and Drug Administration (FDA) for its flagship therapy, Skinject, targeting patients with Gorlin syndrome — a rare, genetic condition affecting about 1 in 31,000 people worldwide and often resulting in lifelong basal cell carcinoma. Medicus has teamed up with the Gorlin Syndrome Alliance (GSA), a patient‑registry organisation representing some 11,000 U.S.–based patients and global connections, to pave the way for access to Skinject outside of traditional clinical trials. CEO Raza Bokhari explained the strategy: Skinject is a non‑invasive microneedle array therapy containing doxorubicin for non‑melanoma skin diseases — aligning innovation with patient advocacy, regulatory momentum and unmet need. The company is leveraging key supporters in Washington, including board‑member and former congresswoman Cathy McMorris Rodgers, to advance its submission. If approved, select patients with Gorlin syndrome could begin using Skinject under compassionate‑use protocols while safety data are still gathered. #MedicusPharma #Skinject #GorlinSyndrome #RareDiseaseTherapy #SlimScan #GrowthStocks #CANSLIM